Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 23Terminated 8Withdrawn 2Unknown 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 41Lymphoid 10Other hematologic neoplasm 6Thoracic 2Gastrointestinal 2CNS 2Other solid neoplasm 1Gynecologic 1Genitourinary 1

Conditions

Mesothelioma, Malignant 1Mesothelioma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 132Cisplatin 129Pemetrexed 114Docetaxel 81Drug Therapy 62Gefitinib 57anlotinib 55Gemcitabine 55Erlotinib Hydrochloride 55Radiotherapy 48Bevacizumab 48pembrolizumab 47Paclitaxel 47Etoposide 44apatinib 42icotinib 41camrelizumab 39osimertinib 36Nivolumab 33Vinorelbine 31Radiosurgery 30sintilimab 29durvalumab 25aumolertinib 25endostar protein 24atezolizumab 22Endostatins 22toripalimab 19Blood Specimen Collection 19tislelizumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Bortezomib × Thoracic × Clear all
NCT00996385 2011-10-31

Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma

Columbia University

Phase 2 Unknown
29 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT00516100 2010-01-15

Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC

Aptium Oncology Research Network

Phase 1/2 Unknown
62 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡